R&D Restructurings Aim To Placate Investors While Pharma Waits For Results
In response to poor R&D productivity and declining revenue as drug patents expire, Big Pharma companies have shrunk drastically to keep shareholders happy while they try to retool moribund R&D strategies.
You may also be interested in...
Sanofi Pulls Back On French Layoff Plans After Government Pressure
Sanofi says it will cut up to 900 jobs in France over the next three years to make its R&D operations there more efficient – that’s less than half the number foreshadowed in July by French trade unions and after the drug maker came under public pressure from the country’s left-wing government.
Swedish Boost For Life Sciences Innovation Resonates Around Europe
Sweden’s government has allocated 4 billion kroner for the R&D sector and SEK 600 million specifically for life science in the hopes of rejuvenating Swedish R&D and getting the nation back on the top rankings of medicine innovation. It’s a theme being heard in other European countries.
European Pharma In Cost-Cutting Mode: Actelion Axes 135 Positions, Sanofi Aims At French R&D Consolidation
Europe's leading biotech Actelion plans to cut 5% of its workforce, while Sanofi considers a major overhaul of its R&D sites in France, as competitive pressures and the European debt crisis continue.